bluebird bio (BLUE) to Present Updated Clinical Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti … – StreetInsider.com
|
bluebird bio (BLUE) to Present Updated Clinical Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti …
StreetInsider.com bluebird bio, Inc. (Nasdaq: BLUE) announced that updated interim data from CRB-401, its Phase 1 study of bb2121, an anti-BCMA CAR T cell therapy being developed by the company and Celgene, will be presented at the American Society of Clinical … |
